Literature DB >> 17003377

B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII.

Simon T Abrams1, Tasneem Lakum, Ke Lin, Gemma M Jones, Andrew T Treweeke, Mosavar Farahani, Mair Hughes, Mirko Zuzel, Joseph R Slupsky.   

Abstract

Signals through the B-cell antigen receptor (BCR) are important for the survival of chronic lymphocytic leukemia (CLL) cells. Therefore, factors that influence these signals have important pathophysiological roles in this disease. One key mediator of BCR signaling is protein kinase C beta (PKCbeta), which regulates the activation of I-kappaB kinases and the deactivation of Bruton tyrosine kinase within the signaling pathways initiated by BCR engagement. The present study demonstrates that overexpression of the PKCbetaII isoform is a feature of CLL cells and that activity of this enzyme strongly correlates with CLL cell response to BCR engagement. Thus, intracellular Ca2+ release and increases in cell survival after BCR cross-linking were significantly greater in CLL patients with low levels than in CLL patients with high levels of active PKCbetaII. Furthermore, BCR-induced Ca2+ fluxes could be restored in CLL patients with high levels of active PKCbetaII by pretreating the cells with the PKCbeta-specific inhibitor LY379196. Conversely, BCR-mediated intracellular Ca2+ release could be inhibited in CLL cells with low levels of active PKCbetaII by pretreatment with the PKC agonist bryostatin. Taken together, these results demonstrate that overexpressed active PKCbetaII plays a role in the regulation and outcome of BCR signals that can be important for the progression of CLL.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17003377     DOI: 10.1182/blood-2006-03-012021

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

Review 1.  Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Varsha Gandhi
Journal:  Expert Opin Investig Drugs       Date:  2012-03-09       Impact factor: 6.206

2.  The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.

Authors:  Viola Biberacher; Thomas Decker; Madlen Oelsner; Michaela Wagner; Christian Bogner; Burkhard Schmidt; Robert J Kreitman; Christian Peschel; Ira Pastan; Christian Meyer Zum Büschenfelde; Ingo Ringshausen
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

3.  The serine-threonine kinase p90RSK is a new target of enzastaurin in follicular lymphoma cells.

Authors:  S Kheirallah; S Fruchon; L Ysebaert; A Blanc; F Capilla; A Marrot; T Alsaati; F X Frenois; K A Benhadji; J J Fournié; G Laurent; C Bezombes
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

4.  Central role of protein kinase Cepsilon in constitutive activation of ERK1/2 and Rac1 in the malignant cells of hairy cell leukemia.

Authors:  Joseph R Slupsky; Aura S Kamiguti; Robert J Harris; John C Cawley; Mirko Zuzel
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 5.  Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Authors:  Lisa Pleyer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil
Journal:  Nat Rev Clin Oncol       Date:  2009-06-02       Impact factor: 66.675

Review 6.  Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia.

Authors:  Julhash U Kazi; Nuzhat N Kabir; Lars Rönnstrand
Journal:  Med Oncol       Date:  2013-10-31       Impact factor: 3.064

7.  Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells.

Authors:  Mercè de Frias; Daniel Iglesias-Serret; Ana M Cosialls; Llorenç Coll-Mulet; Antonio F Santidrián; Diana M González-Gironès; Esmeralda de la Banda; Gabriel Pons; Joan Gil
Journal:  Haematologica       Date:  2009-10-08       Impact factor: 9.941

8.  Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.

Authors:  Xue Wei Meng; Michael P Heldebrant; Karen S Flatten; David A Loegering; Haiming Dai; Paula A Schneider; Timothy S Gomez; Kevin L Peterson; Sergey A Trushin; Allan D Hess; B Douglas Smith; Judith E Karp; Daniel D Billadeau; Scott H Kaufmann
Journal:  J Biol Chem       Date:  2009-11-03       Impact factor: 5.157

9.  Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma.

Authors:  Robert S Boyd; Rebekah Jukes-Jones; Renata Walewska; David Brown; Martin J S Dyer; Kelvin Cain
Journal:  Mol Cell Proteomics       Date:  2009-04-02       Impact factor: 5.911

10.  PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.

Authors:  Dalia El-Gamal; Katie Williams; Taylor D LaFollette; Matthew Cannon; James S Blachly; Yiming Zhong; Jennifer A Woyach; Erich Williams; Farrukh T Awan; Jeffrey Jones; Leslie Andritsos; Kami Maddocks; Chia-Hsien Wu; Ching-Shih Chen; Amy Lehman; Xiaoli Zhang; Rosa Lapalombella; John C Byrd
Journal:  Blood       Date:  2014-07-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.